Skip to main content
spacbrain

CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.

CPSR · NYSE

Trust settledGELESIS HOLDINGS, INC. · Finished

NO ACTION REQUIRED

Nothing left to do

The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.

Cash at settlement

no closing figure

No cash-per-share figure was filed for this vehicle before it finished.

Last close

no quote on file

Daily close

Nothing left to claim

this vehicle finished

There is nothing to hand back: holders who wanted cash elected it at the vote, and the rest became shares in the buyer.

Read what happened to the cash

The floor

Trust settled

This SPAC has finished — its trust was paid out or used to close the deal, so there is nothing left to redeem

Read the reasoning behind this verdict

No price history on file yet — daily closes accumulate from the market data feed.

Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.

SpacBrain’s read

Trust settled

The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

In plain terms

What it is
A SPAC from Capstar Sponsor Group, LLC, listed on NYSE in July 2020.
What it's doing now
It agreed to buy GELESIS HOLDINGS, INC.. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
What you should know
This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.

At a glance

Where it stands
Closed (deSPAC)
The business it bought
GELESIS HOLDINGS, INC.
Industry
the deal record does not name the target's industry yet
Deal value
not stated in the filings we hold
Price vs cash at settlement
no live price on file
Cash in trust when it settled
not yet extracted into a snapshot — the filings below may state it
the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
IPO
6 July 2020
size not on file
Headquarters
501 BOYLSTON STREET, SUITE 6102, BOSTON, MA, 02116
registered in Delaware
Lead underwriter
not extracted from the prospectus yet
Key officers
KUCHERLAPATI RAJU S (Director) · Sannino Alessandro (Lead Project Scientist) · Chiquette Elaine (Chief Scientific Officer)
Listed securities
CPSR common
Cash held per sharenot filed for this window

This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.

Next date that mattersno dated event on file

Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.

Yield to redemption

Nothing left to redeem — no yield to compute.

This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.

What happened to the cash

The reasoning behind the verdict above, in the order the filings establish it.

  1. The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

What has happened, and what is coming

1 dated milestone

Every dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.

  1. 6 July 2020IPOpassed

    IPO size not on file

The deal

terms as filed

What it is buying, on what terms, and how much of the combined company new shares take from you.

  • GELESIS HOLDINGS, INC.—
    closed

    What GELESIS HOLDINGS, INC. does — read from gelesis.com on 26 August 2026

    Gelesis develops GI & Metabolic based biomimetic therapies designed to support physiology and long-term health outcomes. Their proprietary OHS platform is a superabsorbent hydrogel technology that works locally in the GI tract. The company's primary product is Plenity®, an orally administered, non-stimulant, non-systemic aid to weight management indicated for adults with a BMI of 25 to 40 kg/m².

    Medical DevicesWeight ManagementMetabolic Health
    Deal structureSEC-primary — BCA 8-K / S-4 / DEFM14A
    Min-cash condition
    $105M
    Break fee
    $0M
    stated in:0001104659-22-002447 opens on sec.gov in a new tab0000950170-23-027586 opens on sec.gov in a new tab

The score

deterministic, from filed fields

CPSR is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.

Asymmetric return scoreNeither a price nor a cash-per-share figure is on file for this vehicle, and the score is a ratio between the two. Nothing is estimated to fill the gap.

The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.

See the names that are scored, and how

The company

from SEC filings
Read the full profile

CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. was a self-described blank-check company whose common stock traded on the New York Stock Exchange under the ticker CPSR. The company priced its initial public offering on July 6, 2020, under SEC file number 333-239094, as detailed in a 424B4 prospectus with accession number 0001047469-20-003987. The registrant, assigned SEC CIK 0001805087 and SEC SIC industry code 2834 (Pharmaceutical Preparations), filed a 10-K on March 31, 2021, with accession number 0001104659-21-044204. It completed a business combination and no longer files, with a change in shell company status reported in an 8-K filed on January 20, 2022, under accession number 0001104659-22-006034. EDGAR now files this CIK under the name GELESIS HOLDINGS, INC.

Material findings

from the full read of every filing

Every document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.

  • PREM14A25 July 20230001193125-23-192554opens on sec.gov in a new tab

    This is a going-private transaction under the SEC's rules and Parent is already Gelesis's largest stockholder: PureTech beneficially owns 16,727,582 shares, plus options over 155,520 shares, PureTech Warrants over 259,129,542 shares, Legacy Warrants over 216,208 shares and 378,943,720 shares issuable on conversion of Notes. Approval requires both a majority of the shares not owned by Parent or its affiliates and a majority of all outstanding shares. The $0.05664 is stated as a premium of approximately 277.6% over the closing price on June 12, 2023.

  • S-4/A23 December 20210001104659-21-152818opens on sec.gov in a new tab

    The registered count is the maximum expected to be issued to the Gelesis Equityholders and breaks into 74,363,251 shares to holders of Gelesis Common Stock, 18,186,435 that may become issuable under Gelesis Options assumed by New Gelesis, and 4,326,939 issuable on settlement of Gelesis Warrants outstanding as of November 15, 2021, so part of the headline depends on options and warrants rather than on shares delivered at closing. The $9.95 price behind the aggregate is the high-low average of CPSR Class A Common Stock on the New York Stock Exchange on November 18, 2021.

  • S-4/A22 December 20210001104659-21-152723opens on sec.gov in a new tab

    The count is the maximum expected to be issued to the Gelesis Equityholders: 74,363,251 shares to holders of Gelesis Common Stock, 18,186,435 that may become issuable under Gelesis Options to be assumed by New Gelesis, and 4,326,939 issuable on settlement of Gelesis Warrants outstanding as of November 15, 2021. The $9.95 behind the aggregate is the high-low average of CPSR Class A Common Stock on the New York Stock Exchange on November 18, 2021, a market price used for the fee rather than a price agreed for Gelesis.

  • S-4/A14 December 20210001104659-21-149308opens on sec.gov in a new tab

    A large part of the registered count is option and warrant shares rather than closing consideration, so the fee table's ceiling sits well above what changes hands at the Effective Time. The deal itself is struck on an implied equity value of $675 million, with each CPSR Class A and Class B share becoming one share of New Gelesis common stock. The PIPE is 9,000,000 Class A shares at $10.00 for $90 million. On the November 15, 2021 record date the trust held approximately $276,178,675, an estimated $10.01 per share.

  • S-4/A24 November 20210001104659-21-143553opens on sec.gov in a new tab

    The registered count is not all closing consideration: footnote (1) splits it into 74,363,251 shares for holders of Gelesis common stock, 18,186,435 issuable under Gelesis options to be assumed, and 4,326,939 issuable on settlement of Gelesis warrants outstanding as of November 15, 2021. Pricing is $9.95, the NYSE high/low average for CPSR Class A on November 18, 2021. A fee of $116,844.54 was previously paid on August 10, 2021, above the $105,163.94 now computed, so the registered offering has shrunk. The transaction is struck on an implied equity value of $675 million.

  • S-4/A9 November 20210001104659-21-135889opens on sec.gov in a new tab

    The footnote breaks that count into three very different things: 73,728,554 shares to be issued to holders of Gelesis Common Stock, 18,020,033 that may become issuable under Gelesis Options which New Gelesis assumes and which become exercisable on consummation, and 4,290,007 that may become issuable on settlement of Gelesis Warrants outstanding as of November 5, 2021, cancelled at closing in exchange for New Gelesis warrants. Part of the registered count is therefore derivative overhang exercisable later, not stock delivered to equityholders at closing.

Show 3 more material filings
  • S-4/A5 October 20210001104659-21-123149opens on sec.gov in a new tab

    A large part of the registered ceiling is not stock delivered to shareholders at closing: 83,188,403 shares go to holders of Gelesis Common Stock, while 20,865,318 is the maximum that may become issuable under Gelesis Options that New Gelesis assumes, and 4,897,005 the maximum on settlement of Gelesis Warrants outstanding as of August 10, 2021. The assumed option and warrant overhang therefore sits inside the 108,950,726 rather than on top of it, and the merger consideration proper is the smaller figure.

  • S-4/A29 September 20210001104659-21-120804opens on sec.gov in a new tab

    A large part of the registered ceiling is the target's own equity awards rather than merger consideration: 83,188,403 shares go to holders of Gelesis Common Stock, while 20,865,318 may become issuable under Gelesis Options that New Gelesis assumes and becomes exercisable on consummation, and 4,897,005 on settlement of Gelesis Warrants outstanding as of August 10, 2021, which are cancelled in exchange for New Gelesis warrants. That overhang is counted inside the 108,950,726 rather than added to it.

  • S-410 August 20210001104659-21-102963opens on sec.gov in a new tab

    Roughly a quarter of the registered stock is not consideration to shareholders: 83,188,403 shares go to holders of Gelesis Common Stock, while 20,865,318 is the maximum that may become issuable under Gelesis Options that New Gelesis assumes, and 4,897,005 the maximum on settlement of Gelesis Warrants outstanding as of August 10, 2021. Both derivative lines sit inside the registered ceiling rather than on top of it, so 108,950,726 is a fully diluted maximum rather than the closing issuance.

Filings

live EDGAR feed

Everything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.

Show the other 10 filings

The record

The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.

Show the reference detail

Unit structure

Cash in trust at IPOnot extracted from the prospectus

from 424B3 0000950170-23-005948

Trading & liquidity

Average daily volume (20d)no volume reported on the bars we hold
Average daily $ volumeneeds both volume and a live price
Range over the bars heldnot enough price history
Total cash in trustthe trust total is not in the last XBRL stamp

Company profile

Industry (SIC)Pharmaceutical Preparations (2834)
Registered inDelaware
Exchange · CIKNYSE · 0001805087

All filings on EDGARopens on sec.gov in a new tab

Directors & officers

Institutional holders

from SC 13G/13D

Funds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.

Show the declared stakes

13 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.

One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.

News

company wires and the financial press

Reporting we have matched to this ticker. Headlines belong to the outlets that wrote them.

Show the headlines

Sources on file

harvested pages, kept in full

Every public page we have read about this company, stored in full so a source can never go missing.

Show the sources

34 full SEC filing texts archived — searchable, never lost.

In plain English

tap a term to open it

Every piece of jargon this page could have used, and what it actually means.

Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected

A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.

Redemption deadlinethe last day to hand shares back for cash

Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.

Broker action datethe day your broker needs the instruction — earlier than the official date

Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.

Cash in trust / trust per sharethe cash the company is holding for each public share

Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.

Trust discountbuying below the cash held for you

Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.

Dilutionhow much of the company new shares take from you

Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.

Pro-forma equitywhat the company is valued at once the deal closes

The combined company's equity value assuming the announced terms and the redemptions that have actually happened.

ARShow much upside you get per unit of downside

SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.

De-SPACthe day the SPAC becomes the real company

The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.

Outside datethe contractual long-stop for closing the deal

A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.

Accession numberthe SEC's unique id for one filing

Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.

Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since

A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.

Ask the brain

from its filings
Data provenance & audit trail3 internal entries

Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.

CPSR — company record
UNIVERSE-IPO-INDEX2026-08-17

admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 2834 (Pharmaceutical Preparations). The screen found it by filing SHAPE instead — S-1 2020-06-11 → 8-A12B 2020-07-01 → 424B4 2020-07-06 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 2834 + self-described blank check in 424B4 0001047469-20-003987; 424B 0001047469-20-003987 priced 2020-07-06 under S-1 0001047469-20-003522 (file 333-239094, an offering for cash); common ticker CPSR off 10-K 0001104659-21-044204 (2021-03-31); lifecycle EXITED. The pricing prospectus was filed under SEC file number 333-239094, which belongs to S-1 0001047469-20-003522 (2020-06-11) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2020-07-06). Ending PROVEN, not inferred: CLOSED per 8-K 0001104659-22-006034 (2022-01-20) — 8-K item 5.06 "Change in Shell Company Status" (EDGAR item index, items: 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01). EDGAR now files this CIK as "GELESIS HOLDINGS, INC." — the SPAC's own name is kept here and the successor is the target. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

SPONSOR-ID2026-08-14

sponsor "Capstar Sponsor Group, LLC" sourced from prospectus definition (10-K/A) acc 0001104659-21-090259.

Deal — GELESIS HOLDINGS, INC.
UNTAGGED

[CLOSED-RENAME] EDGAR CIK 0001805087 records "CAPSTAR SPECIAL PURPOSE ACQUISITION CORP." ending 2022-01-12; the registrant continues as "GELESIS HOLDINGS, INC.". The rename is the SEC's own record of what the vehicle became, keyed by CIK. Closed 2022-01-12. No deal value is set — a rename says what was acquired, never for how much. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists. [DEAL-STRUCTURE-MINED] minCashM=105, terminationFeeM=0.35 from primary filings (0001104659-22-002447, 0000950170-23-027586).

Back to the screenerVault note